SEC Filing Summary: Galena Biopharma, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Galena Biopharma, Inc. on March 5, 2012. The report addresses a corporate governance event regarding the company's stock listing status on The NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price.
- Last Reported Bid Price: $1.45 (as of March 2, 2012)
Material Changes
The company regained compliance with NASDAQ listing requirements. Specifically, the company satisfied the $1.00 minimum bid price requirement for at least 10 consecutive days in accordance with Marketplace Rule 4310(c).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies beyond the restoration of listing compliance.
Key Facts for Investor Verification
- Confirm the company's continued compliance with NASDAQ minimum bid price requirements.
- Verify the current trading status of Galena Biopharma, Inc. common stock.
- Note that this filing is a status update and does not contain operational or financial performance data.